Alle Studien
Einschreibung auf EinladungPHASE1, PHASE2INTERVENTIONELL

Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy

This research study is looking at a new potential medicine, SRP-1003, for people living with Type 1 Myotonic Dystrophy (DM1). The main goals are to check if the medicine is safe and if the body tolerates it well. Scientists also want to understand how the medicine moves through the body and what effects it has. The study involves giving different doses of SRP-1003, either into a vein or under the skin, or a dummy medicine (placebo). This helps researchers compare the real medicine's effects. Participants will be carefully monitored to see how they react to the treatment. This is an early-stage study, meaning it's one of the first times this medicine is being tested in people with DM1.

Auf einen Blick

Status
Einschreibung auf Einladung
Phase
PHASE1, PHASE2
Sponsor
Sarepta Therapeutics, Inc.
Einschreibeziel
78
Starten
04 Mar 2024
Geschätzte Fertigstellung
31 Dez 2026

Worum geht es in dieser Studie?

This study is an important step in developing new treatments for Type 1 Myotonic Dystrophy (DM1). DM1 is a condition that affects your muscles, making them weak and sometimes making it hard for them to relax after you use them. The new medicine being tested, called SRP-1003, aims to tackle some of the problems caused by DM1.

In this study, researchers want to answer several key questions. Firstly, is SRP-1003 safe for people with DM1, and can their bodies handle it without too many side effects? Secondly, they want to understand how the medicine works in the body – for example, how much of it gets into your system and how long it stays there. Thirdly, they're hoping to see if the medicine has any positive effects on the body's processes related to DM1.

To find these answers, some people in the study will receive SRP-1003, while others will receive a 'placebo', which looks exactly like the medicine but contains no active drug. This is a common way to compare results fairly and find out if any changes are truly due to the new medicine. Because this is an early-stage study, it's about gathering initial information to guide future research.

Wichtige Erkenntnisse

  • This study is testing a new medicine (SRP-1003) for Type 1 Myotonic Dystrophy.
  • It's an early-stage study focusing on safety, how the body handles the medicine, and potential effects.
  • Participants will receive either the new medicine or a dummy medicine (placebo).
  • The medicine will be given into a vein or as an injection under the skin.
  • Strict rules apply for who can and cannot join, including age and medical history.

Wer könnte berechtigt sein?

To join this study, you need to have a confirmed diagnosis of Type 1 Myotonic Dystrophy (DM1) through a genetic test. Your doctor also needs to have noticed clear signs of DM1, including muscle stiffness (myotonia). Your DM1 symptoms must have started after you turned 12 years old, and you must be able to walk at least 10 metres on your own before the study starts. You'll need to be between 18 and 65 years old.

There are also some reasons why you might not be able to join. For example, if you have diabetes that's not well controlled, very high blood pressure that's not under control, or serious heart, liver, or kidney problems. If you have congenital DM1 (a type of DM1 that starts very early in life), or certain infections like HIV or hepatitis B or C, you wouldn't be able to participate. You also shouldn't have had a muscle biopsy in your lower leg in the last three months, or be planning to have one during the study.

If you could become pregnant or make someone pregnant, you would need to use very effective contraception throughout the study and for 90 days after your last dose. You also wouldn't be able to donate sperm or eggs during this time.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Do I have a genetically confirmed diagnosis of Type 1 Myotonic Dystrophy?
  2. Did my DM1 symptoms start after I turned 12 years old?
  3. Can I walk at least 10 meters on my own?
  4. Am I between 18 and 65 years old?
  5. Do I have any serious uncontrolled medical conditions like diabetes, high blood pressure, or heart/liver/kidney disease?
  6. Am I willing to use effective contraception if I could become pregnant or make someone pregnant?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part, you'll first have screening visits to make sure you meet all the study requirements. Once enrolled, you'll either receive SRP-1003 or a placebo, which looks identical but has no active drug. The medicine will be given either into a vein (like a drip) or as an injection under the skin.

Some participants will receive a single dose, while others will receive multiple doses over time. You will have regular appointments at the study clinic for check-ups, blood tests, and other assessments to see how you are doing and how your body is responding to the treatment. These visits help the research team monitor your safety and the medicine's effects. The total length of your involvement in the study will depend on which part of the study you are in (single or multiple doses), but it will involve follow-up after your last dose. You will be told the exact schedule of visits and procedures if you are considering joining.

Potenzielle Risiken und Vorteile

Participating in a clinical trial may offer potential benefits, such as gaining access to a new medicine before it's widely available and contributing to medical knowledge that could help others. However, there are also potential risks, including side effects from the study medicine, or having to spend time on clinic visits and tests. There's no guarantee that the medicine will help you personally. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (35)

  • Liverpool Hospital
    Verifizierte Postleitzahl
    Liverpool, Australia
  • Sunshine Coast University Hospital
    Verifizierte Postleitzahl
    Birtinya, Australia
  • Royal Brisbane And Women's Hospital
    Verifizierte Postleitzahl
    Herston, Australia
  • Alfred Health
    Verifizierte Postleitzahl
    Melbourne, Australia
  • Nucleus Network Brisbane Clinic
    Verifizierte Postleitzahl
    Herston, Australia
  • Mater Hospital Brisbane
    Verifizierte Postleitzahl
    Süd-Brisbane, Australien
  • Universitair Ziekenhuis Gent
    Verifizierte Postleitzahl
    Gent, Belgien
  • UZ Leuven
    Verifizierte Postleitzahl
    Leuven, Belgien
  • University Of Calgary
    Verifizierte Postleitzahl
    Calgary, Kanada
  • University Of Alberta
    Verifizierte Postleitzahl
    Edmonton, Kanada
  • McGill University
    Verifizierte Postleitzahl
    Montreal, Kanada
  • University Hospital of Angers
    Verifizierte Postleitzahl
    Angers, Frankreich

Häufige Fragen

What is Type 1 Myotonic Dystrophy (DM1)?

DM1 is a genetic condition that causes muscles to become weak and can affect how they relax. It can also cause problems in other parts of the body.

Was bedeutet 'placebo-kontrolliert'?

It means some participants will receive the active medicine, while others will receive a 'dummy' medicine (placebo) that looks the same but has no drug in it. This helps researchers compare the true effects of the new medicine.

What does 'Phase 1/2' mean for a study?

These are early stages of research. Phase 1 mainly checks if the medicine is safe and what dose can be given. Phase 2 starts looking at whether the medicine actually works for the condition, as well as continuing to check safety.

Will I know if I'm getting the active medicine or the placebo?

No, this is a 'double-blinded' study, meaning neither you nor the study team will know who is getting the active medicine and who is getting the placebo. This ensures the results are fair and unbiased.

Wie wird das Medikament verabreicht?

The medicine SRP-1003 will be given either into a vein (like a drip in your arm) or as an injection just under the skin.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "Study of SRP-1003 in Participants With Type 1 Myotonic Dystr… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.